BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Isconova Concludes Partnership With Virbac S.A. (FR:PVIRP)


7/25/2012 9:40:58 AM

UPPSALA, July 25, 2012 -- Isconova has concluded a partnership agreement with Virbac – the world's leading pharmaceutical companies in veterinary medicine. In a first step, Isconova’s adjuvant Matrix-M™ will be used by Virbac for the development and improvement of vaccines for the global veterinary market. The first products based on Matrix-M™ are vaccines for dogs against certain infectious diseases. Isconova will receive development milestone payments, and royalties based on Virbac’s future sales of these vaccines.

"We are pleased that Virbac choose to use Matrix-M™ in these new vaccines. This is a further confirmation that Isconova has one of the most promising adjuvants for improving future vaccines in both veterinary and human medicine”, said Sven Andréasson, CEO Isconova.

For further information, please contact:

Sven Andreasson, CEO Isconova

Tel: +46 701 60 60 60, e-mail: sven.andreasson@isconova.com

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix-M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.

Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.com

About Matrix-M ™

Matrix-M ™ is Isconova’s patented adjuvant product for use in human and veterinary vaccines, antibody production and immunological research.

About adjuvants

Adjuvan1s enhance the efficacy of a vaccine or drugs while maintaining safety. Adjuvants increase the vaccine's ability to produce antibodies and induces a cellular response that is important for modern vaccines.

About Virbac

Virbac is a global pharmaceutical Company exclusively dedicated to animal health. Virbac is engaged in the research, development, manufacture and distribution of veterinary products. Virbac's Headquarters is located in Carros, France.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES